Whalesbook
Chalo, ab thoda detail mein dekhte hain ki hua kya hai. Stock market mein aaj Gland Pharma ka share 16.22% tak bhaga hai aur ₹2,170 ke 52-week high ko touch kiya hai. Ye sab hua hai company ke Q4 aur poore saal FY26 ke results aane ke baad. Pharma company ka consolidated profit after tax (PAT) lagbhag double ho gaya, 97% badhkar ₹366.7 crore ho gaya hai. Revenue from operations bhi acche 22% badhkar ₹1,742.8 crore ho gaya iss quarter mein. Analyst expectations se toh yeh numbers kaafi upar hain. Aur toh aur, board ne FY26 ke liye ₹20 per equity share ka final dividend bhi recommend kiya hai. Mazedaar baat ye hai ki jab yeh sab ho raha tha, tab benchmark BSE Sensex 1.14% gir raha tha, matlab Gland Pharma apne dum par chal raha tha.
Ab baat karte hain valuation ki. Itne acche results ke baad bhi, kuch experts ko stock ka valuation thoda zyada lag raha hai. Pichhle 12 mahine ke hisab se P/E ratio lagbhag 36.19 hai, aur kuch estimates ke mutabik yeh 26.31 se 37.05 ke beech mein hai. Matlab, share apne valuation range ke upper side par trade kar raha hai, aur kai analysis mein ise 'very expensive' bhi kaha gaya hai. Haalanki, institutional investors ka stake 40.56% hai, jo confidence dikhata hai. Lekin current P/E se lagta hai ki future growth toh stock price mein pehle se hi include hai. Company ka market cap ₹30,781 crore ke aas paas hai. Abhi jo premium multiples hain, unhein maintain karne ke liye company ko consistently acha perform karna padega aur market share bhi badhana padega. Financial stability ke liye company par sirf ₹243 crore ka low debt hai, jo Divi's Laboratories ki tarah debt-free nahi hai par theek hai.
Yeh jo aaj ka 52-week high hai na, yeh May 2025 ke ₹1,452.20 ke low se ek acchi recovery hai. Market ne results ko positive response diya hai, khaas kar ke pehle ke slow performance ke baad. Par, Indian pharma sector overall FY2026 mein 7-9% grow hone ka estimate hai, lekin aage kuch challenges bhi hain. Jo apna US market hai, uska growth FY2026 mein kam hokar 3-5% ho sakta hai, jo FY2025 mein lagbhag 10% tha. Iska reason global factors aur regulatory issues hain. Industry reports bata rahi hain ki EBITDA margins bhi Q1 FY26 mein lagbhag 42 basis points tak kam ho sakte hain. US mein pricing pressure aur R&D spending badhne ki wajah se aisa ho sakta hai. Gland Pharma ke Q4 mein US market mein 26% YoY growth acchi rahi, par sector slowdown unke growth ko affect kar sakta hai.
Results acche hone ke bawajood, kuch risks hain jin par investors ko dhyan dena chahiye. Gland Pharma ka stock pehle bhi results par volatile raha hai, jaise late 2025 mein girawat ya May 15, 2026 ko record profit ke baad bhi thoda dip. Isse lagta hai ki market sirf immediate results nahi, balki long-term sustainability aur valuation ko bhi dekh raha hai. MarketsMOJO ne March 2026 mein Gland Pharma ko 'Sell' rating di thi, jiska reason tha weakening technical indicators, expensive valuation jo long-term growth se match nahi karta, aur moderate quality metrics. Brokerages ne kuch risks bhi bataye hain, jaise US business mein ongoing pressure aur French subsidiary Cenexi mein der se turnaround. Gland Pharma ka CDMO business toh 28% grow hua hai, par competition aur pricing pressure future margins ko affect kar sakte hain. 36.33 se upar ka P/E ratio matlab future earnings mein koi bhi choti si gadbad stock ko neeche gira sakti hai. Aur haan, pichhle paanch saalon ka negative return, jabki Sensex badha hai, yeh bhi sawal khada karta hai ki company long-term mein shareholder value kaise maintain karegi.